Samsung Biologics buys GSK’s Maryland drug facility for $280M as pharma tariffs loom

A major biomanufacturing footprint just moved onto US soil. Samsung Biologics is buying a drug production site in Rockville, Maryland from GSK for $280M, with plans to expand capacity and upgrade technology. The deal is expected to close by end of Q1 2026, and it plugs directly into the bigger theme: companies racing to “localise” pharma supply chains in case new US import tariffs hit.

What happened

Samsung Biologics America will acquire 100% of Human Genome Sciences Inc in Rockville, Maryland (a US drug production facility) from GSK for $280M.

The site currently has a combined 60,000 litres of drug substance capacity, with additional expansion and technology upgrades planned.

Timing: expected close around the end of Q ...